Alpha 1-antichymotrypsin may be a biomarker for the progression of amnestic mild cognitive impairment
Alpha 1-antichymotrypsin (ACT), an acute-phase protein, has been reported to be increased in the brain and blood of Alzheimer’s disease (AD) patients. However, few previous studies have focused on amnestic mild cognitive impairment (aMCI) patients. The aim of our study was to investigate the changing trend in ACT concentrations during the progression of aMCI. Hence, we measured the cerebrospinal fluid (CSF) and serum levels of ACT in aMCI subjects and normal controls (NC) at 2-year follow-up assessments using ELISA and Western blot. Forty-four NCs, 28 stable aMCI (sMCI) patients, and 20 progressive aMCI (pMCI) patients finished the follow-up assessments, and their data were used for analysis. We found that CSF and serum ACT levels of both sMCI and pMCI patients increased over time, while those of NCs remained stable; CSF and serum ACT levels were significantly higher in both sMCI and pMCI patients than in NCs, except for baseline serum ACT. In pMCI patients prior to developing AD, CSF and serum ACT levels were already significantly higher than those in sMCI patients. The ROC curve results demonstrated that combining CSF and serum ACT levels can distinguish aMCI patients from NCs with high specificity and sensitivity. Our data suggest that ACT may be a biomarker for diagnosing aMCI.
KeywordsAlzheimer’s disease Amnestic mild cognitive impairment Alpha 1-antichymotrypsin Progression Biomarker
Amnestic mild cognitive impairment
Stable amnestic mild cognitive impairment
Progressive amnestic mild cognitive impairment
Mini-mental state examination
Clinical dementia rating
Analysis of variance
The area under the curve
We thank all the subjects for participating in this study and the support by The Sixth Affiliated Hospital of Sun Yat-Sen University.
This study was financially supported by The Natural Science Foundation of Guangdong Province, China (No: Z20140701201710181).
Compliance with ethical standards
Conflict of interest
All authors declared that they have no conflicts of interest to this work.
The ethical committee of The Sixth Affiliated Hospital of Sun Yat-Sen University approved this study and all subjects gave their written informed consent in accord with established human subject research procedures expressed in Declaration of Helsinki.
- 18.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CJ, Kawas CH, Klunk WE, Koroshetz WJ et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269CrossRefGoogle Scholar
- 22.Coutinho AMN, Porto FHG, Duran FLS, Prando S, Ono CR, Feitosa EAAF, Spíndola L, de Oliveira MO, et al (2015) Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects. Alzheimer’s Res Therapy 7(1):58–67CrossRefGoogle Scholar
- 28.Wang J, Song Y, Chen Z, Leng SX (2018) Connection between systemic inflammation and neuroinflammation underlies neuroprotective mechanism of several phytochemicals in neurodegenerative diseases. Oxid Med Cell Longev 2018:1–16Google Scholar
- 30.Su C, Zhao K, Xia H, Xu Y (2019) Peripheral inflammatory biomarkers in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. PsychogeriatricsGoogle Scholar
- 33.Tyagi E, Fiorelli T, Norden M, Padmanabhan J (2013) Alpha 1-antichymotrypsin, an inflammatory protein overexpressed in the brains of patients with Alzheimer’s disease, induces tau hyperphosphorylation through c-Jun N-terminal kinase activation. Int J Alzheimers Dis 2013:606083Google Scholar